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Cancer growth is predicted to require substantial rates of substrate catabolism and ATP
turnover to drive unrestricted biosynthesis and cell growth. While substrate limitation can
dramatically alter cell behavior, the effects of substrate limitation on total cellular ATP
production rate is poorly understood. Here, we show that MCF7 breast cancer cells,
given different combinations of the common cell culture substrates glucose, glutamine,
and pyruvate, display ATP production rates 1.6-fold higher than when cells are limited
to each individual substrate. This increase occurred mainly through faster oxidative
ATP production, with little to no increase in glycolytic ATP production. In comparison,
non-transformed C2C12 myoblast cells show no change in ATP production rate when
substrates are limited. In MCF7 cells, glutamine allows unexpected access to oxidative
capacity that pyruvate, also a strictly oxidized substrate, does not. Pyruvate, when added
with other exogenous substrates, increases substrate-driven oxidative ATP production,
by increasing both ATP supply and demand. Overall, we find that MCF7 cells are
highly flexible with respect to maintaining total cellular ATP production under different
substrate-limited conditions, over an acute (within minutes) timeframe that is unlikely to
result from more protracted (hours or more) transcription-driven changes to metabolic
enzyme expression. The near-identical ATP production rates maintained by MCF7 and
C2C12 cells given single substrates reveal a potential difficulty in using substrate limitation
to selectively starve cancer cells of ATP. In contrast, the higher ATP production rate
conferred by mixed substrates in MCF7 cells remains a potentially exploitable difference.
Keywords: glycolysis, oxidative phosphorylation, Crabtree, ATP supply flexibility, bioenergetic capacity
INTRODUCTION
The ability of cancer cells to respond and adapt to available substrate conditions is widely studied
(1–3), with the primary goals of using cancer cell metabolism to develop diagnostic and therapeutic
strategies. Like any cell, cancer cells must respond to acute fluctuations in substrate availability
to meet the demands for energy and intermediates required to survive and proliferate (4–6).
Over longer time frames, cancer cells adapt to longer-term effects of the microenvironment with
extensive transcriptional and architectural remodeling that enables unrestricted growth in different
tissues and under wide ranges of conditions. A better understanding of both the acute metabolic
responses and longer-term metabolic remodeling is critical to identifying and selectively targeting
metabolism in cancer cells (7, 8).
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Though targeting the metabolic alteration that occurs in
cancer is a long-pursued goal [recently reviewed in (9, 10)], a
successful therapeutic strategy based on metabolic disruption
remains unrealized. Though many observations suggest that
“cancer cell metabolism” is sufficiently different from normal
cellular metabolism to be selectively targetable, the wide
metabolic variation among cancers in different tissues, and even
cells within a tumor, makes it difficult to test this hypothesis
(11–14). Differences that are described as characteristic of cancer
are difficult to interpret. The Warburg effect, for example,
characterized by high rates of glycolysis and/or glucose uptake
(15), has persisted for almost a century (16) despite its ambiguous
definition and non-testable construction with respect to cellular
bioenergetic behavior (17). Proposed mechanisms for the
Warburg effect include altered expression of proteins, including
levels or isoforms of glycolytic enzymes (18), the mitochondrial
pyruvate carrier (19) as a wide variety of specific transcriptional
alterations (20). Taken together, no cohesive model emerges.
Moreover, the hallmark Warburg effect characteristic of high
rates of glucose flux is ambiguous: while faster glycolysis
could represent a consistent shift toward glycolysis, it could
also represent higher ATP demand with no alteration of
catabolic machinery.
An additional problem is the highly responsive nature of
metabolic networks. Unlike earlier models of cancer metabolism
that proposed an irreversible “switch,” most recent models
recognize the high degree of metabolic flexibility that allows a
cancer cell to meet energy and biosynthesis demands even under
rapidly changing conditions (21, 22). Whether this is more true
in cancer cells than other cells is not clear, but limiting such
flexibility should be an advantage if it can be made selective to
cancer. Here, the homeostatic control over steady-state metabolic
flux is a necessary consideration.
Metabolic rates (e.g., rate of glucose catabolism) are controlled
by the concentrations of common intermediates in linked
reactions (e.g., glycolysis) and activities of reactions linking
these intermediates, which are influenced (23) but cannot
be predicted (24) solely by the isoforms and abundance of
the enzymes that carry out those reactions (e.g., hexokinase),
as both concentrations and activities influence these rates.
Analysis of proteomic and transcriptomic data provide a good
understanding of the changes in metabolic machinery that
occur in cancer cells (25), but not of the kinetic behavior
of the metabolic system (26). Distinguishing between the
plastic remodeling of metabolic networks via protein expression
changes and the kinetic function of the network would greatly
strengthen the hypothesis-testing ability of both conceptual and
mathematical metabolic models.
The energy needs of cancer cells are a specific topic of
interest within the larger field of cancer metabolism, where ATP
turnover is presumably increased to meet increased the energy
demand of rapidly growing and dividing cells. Although faster
ATP turnover has been inferred from high rates of glycolysis
in many cancer models [e.g., (27)], clear demonstration of this
is currently lacking. One reason is that many assessments of
energy supply and demand in whole cells end at the raw rates of
associated fluxes, such as oxygen consumption and extracellular
acidification. Because these rates are differently geared to ATP,
and because the units (e.g., pH to moles O2) are not directly
comparable, no combination of these raw rates can yield useful
information about total cellular ATP production when both
pathways are operating. In addition, each of these rates is
confounded by non-ATP-generating portions which must be
empirically determined and subtracted. However, when each raw
rate is properly converted, powerful conclusions can be reached,
including what the rate of total cellular ATP production is, and
how ATP production rate is divided between glycolysis and
oxidative phosphorylation (28).
Existing measurements of ATP production demonstrate their
value in understanding cancer cell energetics. Using the MCF7
epithelial, ER+ breast cancer cell line, Guppy et al. demonstrated
that in contrast to prevailing models of high “aerobic glycolysis”
by these cells, as commonly extrapolated from theWarburg effect
and later applied to the “addiction” of cancer cells to glutamine
and glucose, these cells were primarily oxidative and derived less
than half of their ATP from either glucose or from glutamine
under the conditions assayed (29).
Recent instrumentation advances have greatly simplified the
measurements of ATP production-associated rates in a way that
makes further elucidation of cancer cell bioenergetics, specifically
ATP production and consumption, much more straightforward.
The Agilent XF Analyzer, which measures simultaneous O2 and
H+ fluxes, is one example. However, as mentioned above, these
extracelular flux rates cannot be used to draw conclusions about
total cellular ATP production without correction and conversion
to ATP flux (JATP).
We have developed a method for performing the correction
and conversion needed to calculate rates of glycolytic ATP
production (JATPglyc) and oxidative ATP production (JATPglyc)
rate from all intracellular sources, allowing their summation
to total cellular ATP production (JATPproduction) as well as
determination of the proportional contributions of each ATP-
generating pathway as summarized in theMaterials andMethods
and in Mookerjee et al. (28). Here, we apply this method
to re-examine the bioenergetic behavior of MCF7 cells in
culture. We investigate their ability to use different common
extracellular substrates to meet energy demand, and to determine
how flexibly these cells can meet that demand specifically by
shifting between glycolysis and oxidative phosphorylation. In
addition to flexibility of ATP supply, we also demonstrate
that MCF7 cells display flexibility in the substrate-driven and
maximum rates of ATP production supported by different
substrate conditions. Finally, we demonstrate that increased ATP
supply through recruitment of substrate oxidation is the likely
driver of bioenergetic variation in MCF7 cells.
MATERIALS AND METHODS
Reagents
Chemicals (substrates, drugs, assay medium components) were
from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. Cell
culture reagents were from Corning (Bedford, MA). Seahorse
XF consumables (cartridges, cell culture plates) were from
Agilent (Santa Clara, CA). The bicinchoninic (BCA) assay for
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protein, tetramethylrhodamine methyl ester (TMRM) and other
fluorescence probes were from Life Technologies (Carlsbad,
CA). The FLIPR Membrane Potential Assay Explorer Kit was
from Molecular Devices (Sunnyvale, CA; #R8126 red version).
Zosuquidar was from Cayman Chemical (Ann Arbor, MI).
Cell Culture
MCF7 cells (ATCC) and mouse C2C12 myoblasts (ATCC) were
cultured in Dulbecco’s modified Eagle’s medium (Corning #10-
013) with added 10% (v/v) fetal bovine serum (FBS), 100 units/ml
penicillin, and 100µg/ml streptomycin. Cells were analyzed
within 1 year of purchase from ATCC.
Seahorse XFe96 Assay and Analysis
Twenty four to forty eight hours before the assay, adherent cells
were plated in 100 µl culture medium at 10,000–12,000 cells/well
in the inner 60 wells of a 96-well polystyrene Seahorse V3-PS
Flux plate with no additional coating. Culture mediumwas added
to the remaining outer wells. Twenty five minutes before the
assay start, all wells were washed three times and then incubated
in 180 µl of Krebs-Ringer phosphate HEPES (KRPH) medium
[2mM HEPES, 136mM NaCl, 2mM NaH2PO4, 3.7mM KCl,
1mM MgCl2, 1.5mM CaCl2, 0.1% (w/v) fatty-acid-free bovine
serum albumin, pH 7.4 at 37◦C]. This starvation protocol is
consistent with our prior work and similar to others (30) and
within themeasurement error, measured rates are consistent with
the assumption of exclusive catabolism of added substrates (28).
At the start of the assay, medium was replaced with 180 µl fresh
KRPH at 37◦C. All assays were carried out at 37◦C at a starting
pH of 7.4. Cell respiratory control (31) and glycolytic capacity
(32) were assayed by measuring oxygen consumption and
extracellular acidification rates in a Seahorse XFe96 extracellular
flux analyzer as previously described (28). Cell respiratory control
was assessed by the addition via ports A–D of either 10mM
glucose, 10mM pyruvate, 2mM glutamine, or a mix of all three
in A, followed in all cases by 2µg/ml oligomycin in B, 0.5–1µM
FCCP [carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone]
in C, and 1µM rotenone plus 1µM myxothiazol in D. To
minimize FCCP toxicity dampening maximum respiration rate,
FCCP was carefully titrated in both cell lines prior to performing
experiments. 0.5µM was used for MCF7 cells while 1µM was
used for C2C12 cells. To minimize the potential for energetic
collapse dampening maximum respiration rate after oligomycin
addition, we conducted separate experiments where oligomycin
and FCCP were added simultaneously. The highest rate of
maximum respiration achieved in the presence of oligomycin
and FCCP, whether sequential or simultaneous, was used to
calculate maximum JATPox. Substrate concentrations were close
to common concentrations in cell culture and consistent with our
previous analyses (32, 33).
Glycolytic capacity was assessed with the same substrate
additions as for cell respiratory control in port A, 1µM rotenone
plus 1µM myxothiazol in B, and 100µM monensin in C.
All measurement cycles consisted of a 1min mix, 1min wait,
and 3min rate measurement. Three measurement cycles were
performed prior to any addition, 6 cycles after the port A
substrate addition, and 3 cycles after all subsequent additions.
Assay duration was ∼75min. Following the assay, the cell-
containing plate wells were washed three times with 100 µl
PBS (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM
KH2PO4, pH 7.4@ 22
◦C). 10µl 5.0 % (w/v) sodium deoxycholate
was added to each well and plates were agitated on a plate shaker
at 800 rpm for 5min to lyse cells. Thirty µL water was then
added, and 10 µL of the resulting sample from each well was
analyzed by BCA assay for total protein content calibrated to a
BSA standard. Protein values (µg/well) were used to normalize
the rates of oxygen consumption and extracellular acidification
in each well.
The Wave software native to the XF Analyzer was
used to extract rates of oxygen consumption and
extracellular acidification.
Calculation of ATP Production Rate
(JATPproduction)
We have previously described a method for calculation of total
cellular ATP production rate from extracellular acidification and
oxygen consumption rates (28). This calculation fully accounts
for net ATP production in the cell, including net ATP production
in glycolysis (at phosphoglycerate kinase and pyruvate kinase,
minus consumption at hexokinase and phosphofructokinase),
the TCA cycle (at succinyl CoA synthetase), and by the
mitochondrial ATP synthase. A brief description of the
calculation and its underlying assumptions is presented here.
To calculate JATPglyc, the extracellular acidification rate was
first converted to total proton production rate. The contribution
of respiratory CO2 to total proton production rate was subtracted
to yield glycolytic rate of glucose catabolism terminating in
lactate. This rate was multiplied by the ratio of ATP produced in
glycolysis terminating in lactate per extracellular H+ (the P/H+
ratio). Additional glycolytic flux generating the pyruvate that
is later fully oxidized in the mitochondria generates additional
ATP, and is represented in the mitochondrial respiration rate (see
below). Therefore, mitochondrial respiration rate was multiplied
by the ratio of ATP produced in glycolysis terminating in
pyruvate per O2 consumed for each substrate (P/Oglycolysis).
Glycolytic ATP production (JATPglyc) was calculated as the sum
of these two rates.
To calculate JATPox, mitochondrial respiration rate was
isolated by subtracting from the total oxygen consumption
rate any additional oxygen consumption in the presence
of mitochondrial poisons rotenone and myxothiazol.
Mitochondrial respiration rate was further divided into ATP-
coupled and uncoupled respiration rates using the mitochondrial
ATP synthase inhibitor oligomycin. The ATP-coupled respiration
rate was multiplied by the portion of the P/O ratio attributable
to the mitochondrial ATP synthase (P/Ooxphos). To account for
oxidative substrate-level phosphorylation in the TCA cycle, the
mitochondrial respiration rate was multiplied by the P/O ratio
attributable to succinyl CoA synthetase (P/OTCA). Oxidative
ATP production (JATPox) was calculated as the sum of these
two rates.
Finally, JATPglyc and JATPox were summed to yield the
total cellular ATP production rate, JATPproduction. Note that
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when FCCP (or another mitochondrial uncoupler) is present
and respiration is fully uncoupled, JATPox is theoretical, as
actual oxidative phosphorylation does not occur under these
conditions. Though the biological meaning of the maximum
respiration rate achievable in a cell with the addition of an
uncoupler is not clear, it is generally interpreted as the theoretical
capacity of oxidative phosphorylation (31).
The biological assumptions of the ATP calculation model
include exclusive use of exogenous substrates, proportional use
of single substrates when substrate combinations are given,
complete oxidation of these substrates (for glutamine, partial
oxidation to lactate), transport of reducing equivalents into
the mitochondrial matrix primarily by the malate-aspartate
shuttle, and negligible cell growth under the conditions and
timeframe assayed. Technical assumptions and calibration of
the XF Analyzer measurements have been described previously
(34, 35).
Mitochondrial Membrane Potential
Measurement and Analysis
Absolute mitochondrial membrane potential (1ψM) was
measured by fluorescence microscopy as previously described
(36, 37). Briefly, MCF7 cells were plated in 100 µl culture
medium in Matrigel-coated glass-bottom 96-well culture plates
at 10,000 cells/well 48 h prior to the experiment. Three hours
before recording, cells were washed twice with a modified culture
medium containing TMRM (non-fluorescent DMEM with 10%
FBS, 4.5 mg/L glucose, 1mM NaHCO3, 20mM TES, 1mM
pyruvate, 4mM glutamine, 10 nM TMRM) in an air incubator
at 37◦C in order to equilibrate the probe. Next, the recording
was set up (2 positions/well and 18 wells per plate), and then
cultures were washed 3× with a Potentiometric Medium (PM)
closely resembling the assay medium used for JATPglyc and
JATPox determinations (KRPH; 10 nM TMRM, 1:100 FLIPR,
1µM tetraphenylborate, 1µM zosuquidar) with no substrates.
In order to keep constant probe concentration during the
assay, all media and substrates added to the cultures were
prepared by 1:1 mixing of a common 2×PM (with 32mM
NaCl) with 240mM NaCl (resulting PM), or aqueous stocks of
substrates. Subsequently, after 10min wait, a baseline recording
of 30min was started, followed by 30-min segments of substrate
additions. Imaging was performed on a Nikon Eclipse Ti Perfect
Focus System fully motorized wide-field fluorescencemicroscope
and equipped with a custom Lambda 821 LED light source
(Sutter Instruments, Novato, CA) with Lambda 10-3 emission
filter wheel an Andor iXon Life 888 EMCCD camera (Oxford
Instruments, UK) and a Nikon motorized stage with Elements
5.20 (Nikon, Melville, NY) using an S-Fluor 20× air lens.
TMRM and FLIPR signals were collected at 100 s intervals,
using the following filter sets, given as LED nm, excitation—
emission in nm/bandwidth, for TMRM: 561, 586/20–641/75
(30ms exposure time, 14% power) and for FLIPR: 506, 509/22–
542/27, using a 459/526/596 beamsplitter (30ms, 7%; all from
Semrock, Rochester, NY). Recordings were analyzed in Image
Analyst MKII (Image Analyst Software, Novato, CA) using the
“Mitochondrial membrane potential assay (TMRM/PMPI) with
masking dead cells” standard pipeline. 1ψP and 1ψM were
calibrated using the “Complete Iterative” and “Complete (known
k)” paradigms, respectively, with kT = 0.01 s
−1. To this end,
two calibrants were used; first 1ψM was completely depolarized
using 1µM oligomycin, 1µM FCCP, 4µM antimycin A, 4µM
myxothiazol and 1µM valinomycin (a K+-ionophore) in PM
and the decay in TMRM fluorescence was recorded immediately
for 30min. This was followed by complete depolarization of the
1ψP by adding PM containing 2% paraformaldehyde, 120mM
KCl, and 5µg/mL gramicidin (a Na+ ionophore). The upstroke
of the FLIPR fluorescence intensity upon this calibration step was
used as “Part complete1ψP depolarization,” and each cell in each
viewfield was independently calibrated. Changes in 1ψM after
exogenous substrate addition were calculated and analyzed using
GraphPad Prism and Microsoft Excel.
Statistical Analysis
Statistical analysis was performed in GraphPad Prism. Welch’s
t-test (no assumption of equal standard deviation) was performed
for all pairwise comparisons as described in the figure captions.
For multiple comparisons, ordinary one-way ANOVA followed
by Tukey’s post-hoc multiple comparisons test was performed
as described in figure captions. Technical replicate error (of 3–
6 wells/plate) was discarded. Error bars for all values represent
the standard error of the mean of 4–6 independent experiments
except where noted.
RESULTS
Mixed Substrates Drive Higher Rates of
Total Cellular ATP Production
(JATPproduction) in MCF7 Cells
To determine how JATPproduction in MCF7 cells changes
with substrate provided, MCF7 cells cultured under standard
conditions were briefly starved (25min) to deplete endogenous
substrates (30) and then assayed for extracellular flux of H+
and O2 in the minimal salts buffer KRPH. The extracellular
substrates glucose, glutamine, and pyruvate, either singly or as
a combination of all three, were added during the experiment.
Figure 1A shows the significant variation in JATPproduction that
results under the conditions assayed.
Glucose, glutamine, and pyruvate yielded similar
JATPproduction, of 63.4 ± 2.2, 56.7 ± 3.0, and 57.6 ± 1.8
pmol ATP/min/µg protein, respectively, with no statistically
significant differences. When all three substrates were combined,
JATPproduction increased significantly (p ≤ 0.001) to 91.6 ± 3.7
pmol ATP/min/µg protein. The highest substrate-driven rate
achieved under the conditions tested (91.6 pmol ATP/min/µg
protein, mixed substrates) was 1.6-fold higher than the
lowest recorded substrate-driven JATPproduction of 56.7 pmol
ATP/min/µg protein for pyruvate. The single substrates were
likely being used by cells, as they supported respiration after
the addition of FCCP in the cell respiratory control assays,
while rates in cells receiving no exogenous substrate fell to
zero, presumably through energetic collapse (not shown). The
glycolytic index (GI) values for these substrate conditions
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FIGURE 1 | JATPproduction of MCF7 and C2C12 cells under different substrate conditions. Glycolytic ATP production rate (JATPglyc) and oxidative ATP production rate
(JATPox) are plotted on the x and y axes, respectively. Each data point represents the mean of 4–6 independent experimental replicates ± SEM. Independent replicates
are the average of 3–6 technical replicates per plate. Statistical comparisons were made using ordinary one-way ANOVA with Tukey’s multiple comparisons test.
Dashed diagonal lines represent all possible distributions of JATPglyc and JATPox for the substrate-driven JATPproduction shown. (A) MCF7 cells. (B) C2C12 mouse
myoblast cells.
TABLE 1 | Quantification of MCF7 bioenergetic phenotypes under different
substrate conditions.
MCF7 Bioenergetic Indices by Substrate in KRPH Assay Medium
Glucose Glutamine Pyruvate Mixed
GI (%) 23.6 ± 1.0 −0.1 ± 0.5 9.6 ± 0.3 15.0 ± 0.7
CI (%) 20.2 ± 0.9 – – 12.2 ± 0.6
SFI (%) 100 30 33 100
The Glycolytic Index (GI) describes the percent of total cellular energy production that is
produced by glycolysis; GI= 100*JATPglyc/JATPproduction. The Crabtree Index (CI) describes
the degree to which cells will shift from oxidative to glycolytic ATP production when a
glycolyzable substrate is introduced (or increased); CI = GIcondition2 – GIcondition1, where
condition 1 is prior to substrate addition (here in the absence of exogenous substrates)
and condition 2 is after this addition. Dashes denote conditions not applicable to CI
measurement. The Substrate Flexibility Index (SFI) describes the range over which a cell
can shift between JATPglyc and JATPox to maintain a particular JATPproduction, limited by
the maximum rates of glycolysis and respiration achievable under the conditions given.
Each data point represents the mean of 4–6 independent experimental replicates ± SEM.
Independent replicates are the average of 3–6 technical replicates per plate.
demonstrate that substantial rates of JATPglyc only occurred when
glucose was present (Table 1).
Access to Mixed Substrates Does Not
Consistently Increase JATPproduction in
Cultured Cells
To ask whether the increased JATPproduction in MCF7 cells given
multiple substrates occurs as a function of cell culturing, and
is not intrinsic to these cells, we analyzed another cultured
cell line under the same substrate conditions as the MCF7
cells. Figure 1B shows that the non-transformed C2C12 mouse
myoblast line displayed no significant variation across the
same single- and mixed-substrate conditions; for glucose, 60.1
± 9.8; glutamine, 64.1 ± 6.5; pyruvate, 64.52 ± 6.4; mixed
substrates, 68.9 ± 9.3. There were additionally no consistent
trends in the C2C12 rates between individual experiments,
suggesting no potential for small but meaningful differences
between the substrate conditions as measured. The C2C12
measurements under glucose-only conditions were consistent
with our previously published values for this cell line under the
same conditions (28).
Mixed Substrates Increase JATPproduction by
Increasing JATPox in MCF7 Cells
To understand how changes in JATPproduction occur in the MCF7
cells under different substrate conditions, we examined the
constituent rates of JATPglyc and JATPox in the same dataset
shown in Figure 1A. Figures 2A,B show the composition of
JATPproduction in absolute units, while Figures 2C,D show the
proportional contributions of each pathway in the MCF7 and
C2C12 lines, respectively. Glycolytic ATP production in the
absence of exogenous substrates was 1.6± 0.3 pmol ATP/min/µg
protein (not shown), and changes negligibly with the addition
of glutamine or pyruvate, as expected for these non-glycolyzable
substrates. While pyruvate could be reduced to lactate, the charge
of each molecule is the same and therefore no net acidification
would occur. No significant changes occur in JATPox after the
addition of glutamine or pyruvate individually. JATPproduction
and proportional distribution between JATPglyc and JATPox were
comparable between these cell lines.
In contrast to the single substrates glutamine and pyruvate,
glucose, either alone or combined with glutamine and pyruvate,
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FIGURE 2 | Absolute and proportional JATPglyc and JATPox in MCF7 and C2C12 cells. Absolute rates (pmol ATP/min/µg protein) from Figure 1 are displayed as
stacked columns (A,C) and as percent of total JATPproduction (B,D). Each column represents the mean of 4–6 independent experimental replicates ± SEM. Independent
replicates are the average of 3–6 technical replicates per plate. Statistical comparisons of total JATPproduction were made using ordinary one-way ANOVA with Tukey’s
multiple comparisons test.
recruits glycolysis and drives JATPglyc (Figures 2A,B). The
percentage JATPglyc is the cell’s glycolytic index (GI) value
(Figures 2C,D, Table 1) under the stated conditions. Since
glycolysis requires a glycolysis substrate, JATPglyc would be
expected only from a sugar, e.g., glucose, and the GI index value
should be zero. For glutamine, this is true within the error of
the calculation. For pyruvate, there was a small non-zero rate,
which may represent a source of acidification not accounted for
in the calculation model or an overestimate of the total proton
production rate.
Glucose addition and subsequent JATPglyc was accompanied by
a roughly equal decrease in JATPox, resulting in no net change
to JATPproduction. The illustrates the Crabtree effect (17), and
is quantified in Table 1 as the Crabtree index. When glucose
was the sole substrate, the decrease in JATPox was balanced by
a roughly equal increase in JATPglyc, so that JATPproduction did
not change, and was not significantly different from the rates
conferred by the other single substrates. However, combination
of all three substrates allowed recruitment of JATPglyc similar to
glucose alone, as well as a substantial increase in JATPox, to yield
an overall increase in JATPproduction in the MCF7 cells.
Glutamine, but Not Pyruvate, Confers
Additional Oxidative Capacity in MCF7
Cells
The results above are consistent with an expectation that
glutamine and pyruvate will support similar bioenergetic rates, as
both are respiratory substrates. However, while the JATPproduction
resulting from their individual use was similar, a few notable
differences emerged when cells were driven to their oxidative
capacities under each condition (Table 2, Figure 3). The addition
of the mitochondrial uncoupler FCCP to provoke maximum
respiration did not increase pyruvate-driven respiration past its
substrate-driven rate, suggesting that pyruvate was being used at
its capacity under the conditions measured. In the presence of
glutamine, however, MCF7 cells were able to increase theoretical
JATPox (as a function of respiration) 1.75-fold above its initial
rate (Figure 3A).
C2C12 cells did not appear to utilize glutamine to access
higher rates of JATPox (Figure 3B). Glutamine-driven JATPox in
C2C12 cells did not significantly change with FCCP addition to
drive maximum respiration under the experimental conditions
tested. Pyruvate-driven JATPox was also unable to increase when
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TABLE 2 | Maximum rates and bioenergetic capacities in MCF7 under different
substrate conditions.
Maximum rates of JATPproduction in MCF7 cells in KRPH assay medium
(pmol ATP/min/µg protein)
Glucose Glutamine Pyruvate Mixed
JATPglycmax 149.8 ± 13.8 23.0 ± 4.3 27.0 ± 3.8 154.5 ± 7.8
JATPoxmax 83.4 ± 6.8 98.5 ± 5.7 52.1 ± 1.8 120.2 ± 8.6
Bioenergetic
capacity
233.2 ± 15.4 121.5 ± 7.1 79.1 ± 4.1 274.7 ± 11.5
Maximum rates of JATPglyc and JATPox were determined as described in Methods and
shown in Figure 5. The theoretical bioenergetic capacity is the sum of these values.
Each data point represents the mean of 4–6 independent experimental replicates ± SEM.
Independent replicates represent the average of 3–6 technical replicates per plate.
driven to its theoretical capacity by FCCP. For glucose and
mixed substrates, oxidative capacity was significantly higher than
substrate-driven rates.
Pyruvate, but Not Glutamine, Stimulates
Increased Substrate-Driven JATPproduction
by Increasing JATPox
To resolve how the mixed-substrate condition confers higher
JATPproduction in MCF7, we carried out a pairwise analysis of all
added substrates. We found that pyruvate, in any combination,
was associated with increased JATPproduction similar to the mixed-
substrate condition (Figures 4A,C). Curiously, pyruvate alone
did not confer this effect, supporting the same JATPproduction
as each substrate alone (Figure 1A). Cells using glucose plus
glutamine displayed substrate-driven JATPproduction no different
from either substrate alone (Figure 4B). Similar to Figure 1,
the same analysis of paired substrates in C2C12 cells revealed
no significant differences in JATPproduction between any substrate
pair and each single substrate (Figures 4D–F). Notably, while
glucose alone induced the highest JATPglyc (almost 50% of
JATPproduction), substrate pairs containing glucose shifted to
intermediate positions along the “iso-JATP” line denoting the
same JATPproduction along different proportional contributions
of JATPglyc and JATPox, further supporting the assumption of
exogenous substrate catabolism by the cells. JATPproduction for
each substrate pair is plotted in Figure 4G, together with
the mixed-substrate JATPproduction. The last column shows that
JATPproduction was sensitive to decreased ATP demand caused by
inhibiting protein synthesis using cycloheximide.
Glutamine Allows Access to Additional
Oxidative Capacity in MCF7 Cells by
Increasing ATP Supply Through Substrate
Oxidation
To test possible mechanisms of the increase in JATPox conferred
by substrate combinations containing pyruvate, we measured
mitochondrial membrane potential in MCF7 cells under the
conditions used for extracellular flux analysis. An increase
in cellular JATPox requires an increase in total activities of
substrate oxidation, e.g., by recruitment of additional substrates
FIGURE 3 | Additional oxidative capacity conferred by glutamine but not
pyruvate in MCF7 cells. JATPox for MCF7 (A) and C2C12 (B) under
substrate-driven (hatched bars) and maximum respiration-eliciting conditions
for all substrate conditions assayed. Each column represents the mean of 4–6
independent experimental replicates ± SEM. Independent replicates are the
average of 3–6 technical replicates per plate. Statistical comparisons were
made using ordinary one-way ANOVA with Tukey’s multiple comparisons test.
to feed ATP supply, or an increase in ATP consumption by
additional ATP demand. These supply and demand reactions
are linked by the 1ψM as a common intermediate (31),
which will increase (hyperpolarize) if increased JATPox results
from faster substrate oxidation. Conversely, 1ψM will decrease
(depolarize) if increased JATPox results from increased ATP
demand. Glutamine hyperpolarized 1ψM when it was added
to MCF7 cells in the presence of the other two substrates
(Figure 4H). This indicates an increased activity of substrate
oxidation pathways when glutamine oxidation is recruited, and
this may explain the observed increase in oxidative capacity in
the presence of glutamine (Figure 3A).
Pyruvate Increases JATPox by Increasing
Both Supply and Cellular ATP Demand
In contrast to glutamine, pyruvate added to the other two
substrates did not change 1ψM (Figure 4H). In light of the
increased JATPproduction with pyruvate (Figures 4A–C), pyruvate
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FIGURE 4 | JATPproduction in pairwise substrate combinations. (A–F) Glycolytic ATP production rate (JATPglyc) and oxidative ATP production rate (JATPox) are plotted on
the x and y axes, respectively, for MCF7 (A–C) and C2C12 (D–F) cells catabolizing the substrates indicated. Open symbols indicate single substrates; filled symbols
indicate substrate pairs. Each data point represents the mean of 4–6 independent experimental replicates ± SEM. Independent replicates are the average of 3–6
technical replicates per plate. Statistical comparisons were made using ordinary one-way ANOVA with Tukey’s multiple comparisons test. Dashed diagonal lines
(Continued)
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FIGURE 4 | represent all possible distributions of JATPglyc and JATPox for the substrate-driven JATPproduction shown. (G) MCF7 JATPproduction from substrate pairs with
comparison to mixed substrates and to mixed substrates plus 10µM cycloheximide (CHX). glc, glucose; pyr, pyruvate; gln, glutamine. (H) Change in 1ψM after
addition of the indicated substrates. A pair of substrates (black bars) was followed by the addition of the third substrate (white bars). Data are mean ± SEM of n = 3
independent experimental replicates.
likely independently increased the activities of both supply and
demand. Direct stimulation of ATP demand by pyruvate is
further supported by the finding that the1ψMhyperpolarization
with glutamine did not increase ATP turnover, suggesting that a
change in supply activities is not sufficient to alter ATP demand,
and further that control of overall energy metabolism was largely
by ATP demand.
MCF7 Supply Flexibility and Bioenergetic
Capacity Changes With Substrate
Availability
We previously described how substrate-driven JATPproduction
could be analyzed within the context of cellular bioenergetic
capacity [Figure 5, (28)] to assess the theoretical flexibility of
cellular JATPproduction to increase, decrease, and shift between
JATPglyc and JATPox. We apply that analysis to the MCF7
cells examined here. Figures 5A–D show the substrate-driven
JATPproduction for a different substrate condition; the single
substrates glucose (A), glutamine (B), and pyruvate (C), and the
mixed-substrate condition containing all three (D). Each panel
shows a shaded area representing the theoretical bioenergetic
activity in the cells under each condition. The theoretical
maximum JATPox, as calculated from the respiratory rate
after mitochondrial uncoupling with FCCP in the presence
of oligomycin, forms the horizontal boundary intersecting
the y-axis. Maximum JATPglyc, determined by adding the
Na+-ionophore monensin in the presence of rotenone and
myxothiazol (but not oligomycin, which will inhibit ATP
hydrolysis by themitochondrial ATP synthase), forms the vertical
boundary intersecting the x-axis. Using this convention, we
assessed the ATP supply flexibility of the cell, that is, how
flexibly the cell can meet a given ATP demand by drawing
on JATPglyc and JATPox before it reaches the capacity of either
production pathway.
ATP supply flexibility was quantified using the Supply
Flexibility Index [SFI (28), Table 1]. As shown in Figure 5
and Table 1, MCF7 cells catabolizing glucose displayed a
JATPproduction of 63.4 ± 2.2 pmol/min/µg protein, with 23.6%
of the total JATPproduction derived from glycolysis. JATPglyc and
JATPox were both below their individual maxima (149.8 ± 13.8
and 83.4 ± 6.8, respectively), and the JATPproduction itself was
about half of the theoretical bioenergetic capacity (sum of the
two maxima) of 233.2 ± 15.4 pmol ATP/min/µg protein. To
maintain substrate-driven JATPproduction, the cell therefore had
access to a wide range of its apparent bioenergetic capacity.
ATP supply flexibility was quantified from the angle formed by
lines extending from the origin to the intersection of the iso-
JATP line with the ATP production capacity under the specified
conditions. In cells catabolizing glucose (Figure 5A), the iso-JATP
line extends to each axis without intersecting either capacity,
so that the angle measured at the axis is 90◦. The substrate
flexibility of the MCF7 cells under these conditions was therefore
100∗90/90 = 100%. In other words, MCF7 cells using glucose
had access to 100% of the possible distribution between JATPglyc
and JATPox to meet ATP demand. In contrast, glutamine should
confer no glycolytic capacity and therefore an SFI of zero.
The small calculated JATPglyc that does appear might represent
extracellular acidification in the presence of monensin that is
not accounted for in the calculation model. The calculated SFI
of 100∗26.7/90 = 30% is therefore likely an overestimate of ATP
supply flexibility under these conditions. Similarly, the calculated
SFI of 100∗30/90◦ = 33% for cells oxidizing pyruvate is also
likely to be an overestimate of ATP supply flexibility. Finally,
under the mixed substrate condition, because it contains glucose,
maintenance of substrate-driven JATPproduction was possible with
any combination of JATPglyc and JATPox, yielding an SFI of 100%.
DISCUSSION
We report here that MCF7 cells display considerable bioenergetic
flexibility, demonstrated by their ability to support the
same substrate-driven JATPproduction with different individual
substrates (Figure 1), each with a different catabolic entry point,
and in their ability to support substrate-driven JATPproduction with
any proportional distribution of JATPglyc and JATPox (Figure 5).
We find that this flexibility was not unique to malignant cells,
as non-malignant C2C12 myoblasts, which behave similarly
with respect to JATPproduction, displayed similar flexibilities.
However, MCF7 used its given substrates differently than C2C12
cells, particularly at high JATPproduction. The higher JATPproduction
associated withmixed substrates (Figure 1) appeared to be driven
by pyruvate under substrate-driven conditions (Figure 4), and
by glutamine whenmaximum respiration was elicited (Figure 5).
Interestingly, the comparison between these two cell lines
shows that when provided a glycolysis substrate, MCF7 cells
derived only a small proportion of its total cellular ATP
from glycolysis (about 20%) even when glucose was the sole
exogenous substrate, while the non-malignant C2C12 line was
more glycolytically active both as a proportion of the total
rate (about 50%) and in absolute glycolytic rate, despite similar
JATPproduction to MCF7. The proportional assignment of JATPglyc
and JATPox in MCF7 exactly matched prior determinations of
these ratios made by measuring partial pressures of O2 and
CO2 in closed glass culture chambers (29). This recapitulation
supports the validity of applying our ATP calculation model to
MCF7 cells (28).
These data also demonstrate the error of assuming that
glycolysis produces all or most ATP in cancer cells, a common
extrapolation of the Warburg effect. The Warburg effect is a
useful observation as applied to e.g., tumor detection in vivo
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FIGURE 5 | Bioenergetic capacities and substrate flexibilities in MCF7 cells. Maximum JATPox and JATPglyc determined as described (Methods) for cells catabolizing
exogenous glucose (A), glutamine (B), pyruvate (C), or a mix of all three (D). Boundaries of the shaded boxes represent theoretical (JATPox) or actual (JATPglyc)
capacities, with their x,y intersection the theoretical “bioenergetic capacity” afforded under each tested condition. Shaded area within each box is the theoretical
“bioenergetic space,” or all possible values of JATPglyc and JATPox that the cell could achieve under experimental conditions. Angular notation illustrates supply flexibility
for the substrate-driven JATPproduction shown. Dashed diagonal lines represent all possible distributions of JATPglyc and JATPox for the substrate-driven JATPproduction
shown, within the bioenergetic capacities represented by the x- and y- boundaries of the shaded box. Each point and capacity represents the mean of 4–6
independent experimental replicates ± SEM. Independent replicates are the average of 3–6 technical replicates per plate.
using positron tomography, but cannot be similarly applied
to characterizing cancer cells in vivo or in cell culture, or to
understanding their bioenergetic behavior.
The 1.6-fold, or 60% increase between the highest and
lowest JATPproduction by MCF7 represents a substantial range
of substrate-driven flux. The main driver of this increase
appeared to be pyruvate oxidation, in combination with either
glucose or glutamine but not alone. Pyruvate-driven increases
in JATPox appeared to be due to roughly equal increases in
ATP supply and ATP demand, as 1ψM hyperpolarization
was relatively small (∼1mV, Figure 4H). In contrast, the
presence of glutamine in any combination triggered a much
more substantial hyperpolarization (∼7mV) indicating faster
ATP supply. Glutamine-driven 1ψM hyperpolarization did
not consistently correspond to faster JATPox (Figure 4B).
Because glutamine did not increase JATPproduction (Figure 4B),
despite the 1ψM hyperpolarization, it is possible that
1ψM has a weak control over ATP demand, i.e., higher
ATP/ADP in the presence of more negative 1ψM does not
drive demand reactions faster, so JATPox does not show a
net increase.
Additionally, while the substrate-driven rates in both cell
types supported by glutamine alone or by pyruvate alone were
all similar, their oxidative capacities diverged considerably, with
glutamine conferring substantially higher rates than pyruvate.
One possible explanation for pyruvate’s lack of ability to
support additional capacity across both cell lines is artifactual;
FCCP-mediated 1ψM collapse to drive maximum respiration
rate could selectively slow H+/pyruvate symport into the
mitochondrial matrix. If so, pyruvate-mediated JATPox might be
higher with intact membrane potential but not detectable under
our experimental conditions.
For glutamine, the different responses of C2C12 and MCF7
could represent differences in the architecture of glutamine
Frontiers in Oncology | www.frontiersin.org 10 November 2020 | Volume 10 | Article 1703
Louie et al. ATP Supply Flexibility in MCF7 Cells
oxidation between the two cell types. This observation may
explain at least in part why a cancer cell might appear to be
“glutamine-addicted,” if glutamine withdrawal deprives cells of
access to a portion of its capacity that cannot be accessed by
pyruvate or other substrates. Prior work on the iBMK cell line
supports a substantial contribution of glutamine oxidation to
ATP production (38), though this may vary by cell type (29).
Further, as uncoupled respiration is controlled primarily by
substrate oxidation, changes in the protein levels of substrate
oxidation machinery, includine glutamine transporters (39) or
catabolic enzymes (40), may underlie differences in capacity that
are not detectable in the substrate-driven rates, in which control
by ATP demand is much greater.
The maximum JATPglyc (JATPglyc|max) calculated for glutamine
and pyruvate (Figure 5) were surprising, since glycolytic capacity
from exclusive catabolism of non-glycolytic substrates was
expected to be zero. These calculated rates likely result
either from an overestimate of acidification rate, or from
a true acidification rate not accounted for by respiratory
CO2, In either case, these rates probably do not represent
true JATPglyc. Overestimated JATPglyc|max would also cause
overestimation of SFI values and bioenergetic capacities,
which are both determined using JATPglyc|max. Since our
major findings of (1) full ATP supply flexibility at substrate-
driven JATPproduction for both MCF7 and C2C12 cells, (2)
JATPproduction responsive to substrate composition in MCF7,
and (3) the ability of MCF7 to access additional oxidative
capacity using glutamine, are not reliant on JATPglycmax, potential
error in the calculation of JATPglycmax do not change our
major conclusions.
However, these discrepancies do highlight some of the
limitations of the ATP calculation model. The assumptions
underlying the conversion of extracellular H+ and O2 flux to
JATPglyc and JATPox, allowing determination of JATPproduction, are
fully validated for glucose, but not for glutamine or pyruvate,
in an intact-cell system. We find negligible contributions
attributable to fluxes other than through glycolysis and
oxidative phosphorylation under the conditions assayed (with
the exception of JATPglycmax), suggesting that deviations from the
model are small. However, this calculation is currently reliable
only for non-growing cells, as growth would change the H+/O2
and P/O ratios on which the calculation relies. This represents
a potential limitation on applying these findings to rapidly
growing cells. In addition, this approach would fail to detect the
potentially significant operation of pathways whose sum of errors
happens to be small.
In conclusion, we demonstrate here that despite the common
constraints of cell culturing in the same medium, MCF7 cancer
cells display notable differences from a non-cancer cell type
that are consistent with, and further refine, existing models of
metabolic flexibility in cancer, including a potential bioenergetic
basis for the hypothesis that glutamine oxidation provides access
to bioenergetic capacity not afforded by other oxidized substrates.
In contrast to many prevailing models of cancer cell metabolism,
these differences do not always include substrate-driven ATP
supply flexibility, greater ATP demand, or a greater reliance on
glycolysis to meet ATP demand.
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